{"gene":"ANGPTL4","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2000,"finding":"ANGPTL4 (FIAF) is a PPARα target gene identified by subtractive hybridization; it is predominantly expressed in adipose tissue, secreted into blood plasma, and plasma levels increase with fasting and decrease with chronic high-fat feeding, establishing its role as a fasting-regulated endocrine factor.","method":"Subtractive hybridization (SABRE), mRNA quantification, plasma protein detection across wild-type and PPARα-null mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — foundational discovery using multiple methods in genetic knockout model, replicated across tissues","pmids":["10862772"],"is_preprint":false},{"year":2005,"finding":"Recombinant ANGPTL4 protein directly inhibits LPL activity in vitro; transgenic overexpression of human ANGPTL4 in liver elevates plasma triglycerides and reduces post-heparin LPL activity, while ANGPTL4-deficient mice show hypotriglyceridemia and increased LPL activity, with greater effect in the fasted state.","method":"In vitro LPL inhibition assay with purified recombinant protein; transgenic overexpression; targeted gene disruption in mice; post-heparin plasma LPL activity measurement","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution plus complementary genetic gain- and loss-of-function mouse models","pmids":["16081640"],"is_preprint":false},{"year":2009,"finding":"ANGPTL4 forms dimers and tetramers intracellularly before secretion; it is cleaved by a proprotein convertase at RRKR(164), releasing an oligomeric N-terminal domain and monomeric C-terminal fibrinogen-like domain. Oligomerization, but not cleavage, is required for LPL inhibition. The E40K variant is synthesized and processed normally but N-terminal oligomers fail to accumulate extracellularly, abolishing LPL inhibition.","method":"Expression in HEK-293A cells; mutagenesis of oligomerization and cleavage sites; LPL activity assays; in vivo validation in mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis plus in vitro enzymatic assay, validated in vivo","pmids":["19270337"],"is_preprint":false},{"year":2012,"finding":"ANGPTL4 mediates fasting-induced intracellular lipolysis in white adipose tissue downstream of glucocorticoid receptor activation; ANGPTL4 stimulates cAMP signaling upstream of adenylate cyclase and downstream of receptor activation in adipocytes, and purified human ANGPTL4 alone is sufficient to increase cAMP and induce lipolysis in primary Angptl4−/− adipocytes.","method":"Angptl4 knockout mice; glucocorticoid receptor blockade; primary adipocyte treatment with purified human ANGPTL4; cAMP measurement; phosphorylation of lipolytic enzymes; pharmacological dissection of signaling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — purified protein reconstitution in knockout cells, multiple pharmacological probes, in vivo confirmation","pmids":["22267746"],"is_preprint":false},{"year":2012,"finding":"Tissue-specific cis-regulatory modules within angptl4 intron 3 drive expression in liver, pancreatic islet β-cells, and intestinal enterocytes in zebrafish; the microbiota suppresses the transcriptional activity of the intestine-specific regulatory module, thereby reducing intestinal Angptl4 expression.","method":"Transgenic reporter assays in zebrafish; gnotobiotic colonization; site-directed mutagenesis of regulatory sequences; comparative sequence analysis across 12 teleost species","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo transgenic reporters with mutagenesis and gnotobiotic functional validation","pmids":["22479192"],"is_preprint":false},{"year":2013,"finding":"Butyrate induces intestinal ANGPTL4 expression via a PPARγ-independent, butyrate-responsive element ~0.5 kb upstream of the transcription start site, while PPARγ ligands act on a downstream PPAR-responsive element; these two pathways are additive.","method":"RT-PCR; promoter dissection; PPARγ inhibitor and siRNA experiments; germ-free mouse colonization with Clostridium tyrobutyricum; butyrate gavage","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological dissection of two independent promoter elements, validated in germ-free mice","pmids":["23518684"],"is_preprint":false},{"year":2014,"finding":"In non-exercising muscle during acute exercise, ANGPTL4 is induced by elevated plasma free fatty acids via PPARδ activation; in exercising muscle, ANGPTL4 induction is counteracted by AMPK-mediated downregulation, promoting local triglyceride uptake as fuel.","method":"Human biopsy studies; animal exercise models; in vitro PPARδ and AMPK manipulation; combination of human, animal, and cell data","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multi-level (human/animal/cell) orthogonal data demonstrating FFA-PPARδ induction and AMPK-mediated suppression","pmids":["24591600"],"is_preprint":false},{"year":2015,"finding":"Adipose-derived Angptl4 links glucagon receptor antagonist-induced adipose triglyceride metabolism to α-cell proliferation; Angptl4 is upregulated via PPARγ activation in white adipose tissue following glucagon receptor antagonist treatment, and Angptl4 supplementation specifically promotes α-cell proliferation, while Angptl4 knockout mice treated with glucagon receptor antagonist do not show increased glucagon or α-cell proliferation.","method":"Angptl4 knockout mice; glucagon receptor antagonist treatment; Angptl4 protein supplementation; pancreatic α-cell quantification","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic KO epistasis combined with protein supplementation rescue and defined cellular readout","pmids":["26621734"],"is_preprint":false},{"year":2016,"finding":"ANGPTL4 loss-of-function mutations in humans (including E40K) are associated with 35% lower triglyceride levels and protection from coronary artery disease; monoclonal antibody inhibition of Angptl4 in mice and monkeys reduces triglyceride levels, confirming LPL inhibition as the functional mechanism.","method":"Exome sequencing of 42,930 participants; genetic association study; anti-ANGPTL4 monoclonal antibody in mice and non-human primates; lipid measurements","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 — large-scale human genetics corroborated by pharmacological inhibition in two animal species","pmids":["26933753","26934567"],"is_preprint":false},{"year":2017,"finding":"Glucocorticoid-induced insulin resistance is mediated by Angptl4: Angptl4 stimulates lipolysis in white adipose tissue, raising fatty acid flux to the liver and increasing hepatic ceramide synthesis via ceramide synthetic enzymes. Ceramide then activates PP2A and PKCζ to impair insulin signaling. Pharmacological inhibition of ceramide synthesis or PKCζ rescued glucose intolerance in wild-type but not Angptl4-null mice.","method":"Angptl4 knockout mice; metabolomic profiling; PP2A and PKCζ activity assays; ceramide synthesis inhibitors; genetic epistasis","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 — metabolomics, enzymatic assays, pharmacological and genetic epistasis across multiple orthogonal methods","pmids":["28743803"],"is_preprint":false},{"year":2018,"finding":"Crystal structures of the fibrinogen-like domains of ANGPTL4 (and ANGPTL3) were solved, providing structural insights into loss-of-function mutation sites and potential mechanisms of LPL interaction.","method":"X-ray crystallography of fibrinogen-like domain","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1 — crystal structure, but functional validation is limited and primarily structural insight","pmids":["29713054"],"is_preprint":false},{"year":2018,"finding":"Adipose tissue-specific deletion of ANGPTL4 results in enhanced LPL activity, rapid clearance of circulating TAGs, increased adipose lipolysis and fatty acid oxidation, decreased hepatic ectopic lipid deposition, reduced nPKC membrane translocation, improved insulin signaling, improved glucose tolerance, and attenuated atherosclerosis in high-fat diet-fed mice.","method":"Adipose-specific Angptl4 knockout mice; LPL activity assays; metabolic turnover studies; insulin signaling assays; atherosclerosis quantification","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific KO with multiple defined metabolic and cellular readouts","pmids":["29563332"],"is_preprint":false},{"year":2018,"finding":"Brown adipose tissue-specific deletion of ANGPTL4 results in enhanced LPL activity, increased circulating TAG clearance, increased fatty acid oxidation, reduced fatty acid synthesis, improved glucose tolerance, and enhanced thermogenesis during cold exposure.","method":"BAT-specific Angptl4 knockout mice; LPL activity assays; fatty acid oxidation and synthesis measurements; cold exposure thermogenesis assay","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific KO with multiple defined metabolic readouts","pmids":["29627378"],"is_preprint":false},{"year":2018,"finding":"In exercising skeletal muscle, Angptl4 treatment activates AMPK signaling (phosphorylation of AMPK and ACC) and increases mitochondrial maximum respiratory capacity; Angptl4-knockout mice show attenuated exercise-induced AMPK phosphorylation and reduced exercise endurance.","method":"C2C12 myotube treatment with recombinant Angptl4; Angptl4 knockout mice; treadmill and swimming endurance tests; AMPK/ACC phosphorylation assays","journal":"Journal of applied physiology","confidence":"Medium","confidence_rationale":"Tier 2 — direct protein treatment in cells combined with KO mouse data, but single lab","pmids":["29952246"],"is_preprint":false},{"year":2019,"finding":"TAZ directly regulates ANGPTL4 as a target gene; ANGPTL4 sensitizes ovarian cancer cells to ferroptosis by activating NOX2; TAZ removal confers ferroptosis resistance whereas constitutively active TAZ enhances susceptibility via the ANGPTL4-NOX2 axis.","method":"TAZ knockdown and overexpression; ANGPTL4 depletion; NOX2 activity assays; ferroptosis assays in ovarian cancer cell lines; integrative genomic analysis","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 — epistatic genetic dissection with functional ferroptosis readout, single lab","pmids":["31641008"],"is_preprint":false},{"year":2019,"finding":"ANGPTL4 from MSCs is induced by RORα in response to inflammatory mediators (IL-1β); RORα binds the ANGPTL4 promoter; ANGPTL4 secreted by MSCs suppresses macrophage polarization toward the pro-inflammatory phenotype, and ANGPTL4-deficient MSCs fail to inhibit inflammatory macrophage polarization.","method":"MSC-macrophage co-culture; ANGPTL4-deficient MSC generation; ChIP demonstrating RORα binding to ANGPTL4 promoter; peritonitis and myocardial infarction animal models","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP, KO MSC epistasis, in vivo model, single lab","pmids":["31434807"],"is_preprint":false},{"year":2020,"finding":"ANGPTL8 forms complexes with ANGPTL4, and the ANGPTL4/8 complex has >100-fold reduced LPL-inhibitory activity compared to ANGPTL4 alone; conversely ANGPTL3/8 has >100-fold increased LPL-inhibitory activity vs ANGPTL3 alone. Insulin increases ANGPTL4/8 secretion from adipocytes, which during feeding blocks ANGPTL4-mediated LPL inhibition in adipose tissue, directing fatty acids toward fat storage.","method":"Quantitative LPL inhibition assays with recombinant proteins and complexes; immunoassay quantification of complexes in human serum; competition experiments; hepatocyte and adipocyte insulin treatment","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1-2 — quantitative reconstituted in vitro assay, validated with human serum measurements and cell experiments","pmids":["32487544"],"is_preprint":false},{"year":2020,"finding":"Oleic acid induces ANGPTL4 expression in colorectal cancer cells; ANGPTL4 is required for c-Jun-mediated transactivation of NOX4, leading to increased ROS and upregulation of MMP-1 and MMP-9, promoting cancer cell metastasis. ANGPTL4 depletion abrogates oleic acid-induced NOX4 induction and metastatic seeding.","method":"ANGPTL4 knockdown; NOX4 transcription assays; ROS measurement; MMP expression; in vitro invasion assays; in vivo tumor extravasation model","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 — knockdown epistasis with mechanistic signaling readouts in vitro and in vivo, single lab","pmids":["32641980"],"is_preprint":false},{"year":2021,"finding":"ANGPTL4 promotes the unfolding of LPL leading to LPL cleavage and subsequent degradation in adipocytes; ANGPTL8 opposes this by keeping LPL active after feeding. In macrophages and cardiomyocytes, ANGPTL4 acts as a lipid-inducible feedback regulator of LPL-mediated lipid uptake. In hepatocytes, ANGPTL4 functions as a local inhibitor of hepatic lipase.","method":"Review integrating mechanistic studies from multiple labs (genetic models, biochemical assays, unfolding experiments)","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1-2 — synthesis of replicated biochemical and genetic findings across multiple labs; LPL unfolding mechanism established by structural/biochemical studies","pmids":["34801488"],"is_preprint":false},{"year":2021,"finding":"Hepatocyte-specific Angptl4 deficiency increases hepatic lipase (HL) activity, facilitating catabolism of TAG-rich lipoprotein remnants in the liver, reducing circulating TAG and cholesterol; it also promotes fatty acid uptake leading to increased fatty acid oxidation, ROS production, and AMPK activation in hepatocytes.","method":"Hepatocyte-specific Angptl4 mutant mice; metabolic turnover studies; hepatic lipase activity assays; fatty acid oxidation measurement; AMPK activation assays; liver-targeted antisense inhibition","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific genetic model with multiple mechanistic readouts and pharmacological validation","pmids":["34255741"],"is_preprint":false},{"year":2021,"finding":"ANGPTL4 is a more potent inhibitor of endothelial lipase (EL) than ANGPTL3; formation of the ANGPTL4/8 complex markedly reduces ANGPTL4's EL-inhibitory activity, while ANGPTL3/8 complex formation increases EL inhibition compared to ANGPTL3 alone.","method":"In vitro recombinant protein EL inhibition assays; comparison of ANGPTL3, ANGPTL4, ANGPTL3/8, and ANGPTL4/8 complex activities","journal":"Heliyon","confidence":"High","confidence_rationale":"Tier 1 — quantitative in vitro enzymatic assay with purified recombinant proteins","pmids":["34504977"],"is_preprint":false},{"year":2022,"finding":"Genetic mimicry analysis in >110,000 individuals demonstrates that ANGPTL4 suppression is highly concordant with LPL enhancement but not with hepatic lipase or EL suppression, indicating ANGPTL4 modulates plasma lipid parameters exclusively via LPL in humans.","method":"Human genetic mimicry analysis using UK Biobank (>110,000 subjects) and validation in 11 European populations; variant-level concordance analysis across 248 metabolic parameters","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — large-scale human genetic evidence, validated in independent populations with mechanistic specificity","pmids":["36372100"],"is_preprint":false},{"year":2023,"finding":"ANGPTL4 inhibits LPL by destabilizing lid-anchoring structures via binding overlapping with the APOC2 binding site on LPL; ANGPTL4 decreases LPL thermal stability and promotes irreversible unfolding of LPL's α/β-hydrolase domain, whereas APOC2 binding to the same region stabilizes LPL and protects it from unfolding.","method":"Hydrogen-deuterium exchange mass spectrometry (HDX-MS) mapping of binding sites on LPL; thermal stability assays; comparison of ANGPTL4 and APOC2 effects on LPL conformation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — HDX-MS structural mapping with functional thermal stability readouts revealing mechanism of LPL inactivation","pmids":["37094117"],"is_preprint":false},{"year":2023,"finding":"TGFβ stimulates ANGPTL4 vesicle trafficking and secretion through formin-like 2 (FMNL2); PKC-dependent phosphorylation of FMNL2 downstream of TGFβ is required; FMNL2 directly polymerizes actin at ANGPTL4-containing vesicles (associated with Rab8a and myosin Vb) to facilitate their mobility and cancer cell invasion.","method":"Super-resolution microscopy; FMNL2 knockdown and phosphorylation mutants; PKC inhibition; co-localization studies; actin polymerization assays at vesicles; invasion assays","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — super-resolution imaging with genetic and pharmacological mechanistic dissection, single lab","pmids":["36691769"],"is_preprint":false},{"year":2023,"finding":"ANGPTL4 treatment in atherosclerotic Apoe−/− mice reduces vascular smooth muscle cell (SMC) phenotypic transition to macrophage-like cells by reducing TNFα-induced NOX1 activation, thereby suppressing KLF4 expression and preventing SMC dedifferentiation; this stabilizes atherosclerotic plaques by increasing fibrous cap thickness.","method":"ANGPTL4 protein injection in Apoe−/− mice; SMC phenotype assays (α-SMA, SM22α, KLF4, CD68 staining); NOX1 assays; fibrotic cap morphometry","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo protein treatment with mechanistic signaling readouts, single lab","pmids":["36782020"],"is_preprint":false},{"year":2024,"finding":"Podocyte- and tubule-secreted ANGPTL4 interacts with Integrin β1 and influences the association between dipeptidyl peptidase-4 (DPP4) and Integrin β1; this interaction drives fibrogenic signaling including STING pathway activation, pro-inflammatory cytokine expression, EMT, and mitochondrial damage in diabetic kidney disease.","method":"Podocyte- and tubule-specific Angptl4 mutant mice; diabetes model; co-IP/binding assays between ANGPTL4, Integrin β1, and DPP4; STING pathway assays; kidney-targeted antisense inhibition","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 — tissue-specific KO, binding interaction assays, and pharmacological rescue, single lab","pmids":["39630889"],"is_preprint":false},{"year":2020,"finding":"Fasting in humans increases ANGPTL4 mRNA (+90%) and protein (+46%) in subcutaneous adipose tissue coincident with a 60% reduction in adipose LPL activity, without changes in LPL mRNA or protein; cortisol and fatty acids upregulate ANGPTL4 in primary human adipocytes while insulin downregulates it.","method":"Human clinical study with adipose biopsies before and after 26-h fast; LPL activity assay; ANGPTL4 mRNA and protein quantification; primary human adipocyte treatment with cortisol, fatty acids, and insulin","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 — prospective human biopsy study with multiple molecular readouts, corroborated by primary cell experiments","pmids":["32504883"],"is_preprint":false},{"year":2020,"finding":"ANGPTL4 deficiency in haematopoietic cells promotes monocyte/myeloid progenitor expansion and atherosclerosis; macrophage ANGPTL4 deficiency increases CD36 expression and reduces ABCA1 surface localization, promoting foam cell formation; ANGPTL4-deficient common myeloid progenitors have higher lipid raft content and are more proliferative and less apoptotic.","method":"Bone marrow transplantation; atherosclerosis quantification; flow cytometry of myeloid progenitors; CD36 and ABCA1 expression and localization assays; lipid raft staining","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — haematopoietic-specific KO with multiple cellular mechanism readouts, published in high-impact journal","pmids":["27460411"],"is_preprint":false},{"year":2019,"finding":"PPARβ/δ represses ANGPTL4 transcription in the absence of ligands by recruiting NCOR (identified as the main interactor by mass spectrometry), which reduces recruitment of Mediator subunits, RNA polymerase II, and TFIIB to the ANGPTL4 promoter; this repression is partially HDAC-independent.","method":"ChIP assays; mass spectrometry identification of PPARβ/δ interactors; PPARβ/δ mutant reconstitution in KO cells; RNA polymerase II and general transcription factor occupancy assays","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP, MS interactome, and mutant reconstitution, single lab","pmids":["31428774"],"is_preprint":false},{"year":2020,"finding":"Calcineurin (CaN) inhibitors reduce ANGPTL4 expression in podocytes via suppression of Nfatc1; ChIP assays demonstrate that Nfatc1 directly binds the Angptl4 promoter and increases its transcription; overexpression of ANGPTL4 in podocytes induces cytoskeletal rearrangement, reduces synaptopodin, and enhances apoptosis.","method":"PAN-induced nephrotic syndrome rat model; CaN inhibitor treatment; Nfatc1 overexpression and knockdown; ChIP assays; podocyte cytoskeletal and apoptosis assays","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP showing direct transcription factor binding, genetic overexpression/KD with cellular readouts, single lab","pmids":["32686149"],"is_preprint":false},{"year":2024,"finding":"CAF-secreted ANGPTL4 binds to IQGAP1 on prostate cancer cell membranes, activating the Raf-MEK-ERK-PGC1α axis to promote mitochondrial biogenesis and oxidative phosphorylation metabolism, thereby facilitating cancer cell growth and chemoresistance.","method":"GST pull-down assay; Co-IP; proteomics of conditioned media; metabolomics; IQGAP1 inhibitor screening; in vitro and in vivo cancer models","journal":"Journal of advanced research","confidence":"Medium","confidence_rationale":"Tier 2 — GST pulldown and Co-IP establishing direct binding, with metabolomics and signaling pathway readouts, single lab","pmids":["39647634"],"is_preprint":false},{"year":2024,"finding":"SMAD3 (activated by TGF-β1 secreted by adipose-derived stem cells) directly binds to the ANGPTL4 promoter as shown by chromatin immunoprecipitation, upregulating ANGPTL4 transcription in colorectal cancer cells to promote glycolysis and anoikis resistance.","method":"ChIP assay; RNA sequencing; co-culture with adipose-derived stem cells; ANGPTL4 knockdown; in vivo peritoneal seeding model","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP demonstrating direct transcription factor binding, validated with KD epistasis in vivo, single lab","pmids":["38643448"],"is_preprint":false},{"year":2024,"finding":"ANGPTL4/8 complex and the C-terminal domain-containing ANGPTL4 (CD-ANGPTL4) fragment are positively associated with inflammation (CRP), diabetes prevalence, and cardiovascular mortality in two independent large cohorts; ANGPTL3/8 potently inhibits GPIHBP1-bound LPL activity in recombinant protein assays.","method":"Recombinant protein LPL activity assay with GPIHBP1; dedicated immunoassays for ANGPTL3/8, ANGPTL4/8, CD-ANGPTL4 in 2394 LURIC and 6188 getABI participants; longitudinal outcome analysis","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro enzymatic assay plus large-scale human observational validation, single lab","pmids":["39392008"],"is_preprint":false},{"year":2022,"finding":"Angptl4 modulates monocyte-to-macrophage differentiation during wound healing via regulation of interferon activated gene ifi202b; Angptl4-mediated kinome signaling (involving S6K, JAK, CDK) controls ifi202b expression; silencing ifi202b in Angptl4-deficient monocytes rescues impaired monocyte-to-macrophage transition in vitro.","method":"Flow cytometry; single-cell RNA sequencing; unbiased kinase inhibitor screen; siRNA rescue experiments; Angptl4 knockout and LysM-specific knockout mice; wound healing models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — scRNA-seq, KO models, kinase screen, and siRNA rescue, single lab","pmids":["35210411"],"is_preprint":false},{"year":2009,"finding":"Induction of ANGPTL4 expression in airway smooth muscle cells by PKC activators requires activation of the Ras-MEK1/2-ERK1/2 pathway and the JNK pathway, but not the p38 MAPK pathway; knockdown of PKCα, MEK1/2, or JNK1/2 inhibits PMA-induced ANGPTL4 upregulation.","method":"PKC inhibitors; specific kinase inhibitors (U0126, SP600125, manumycin A); siRNA knockdown of PKCs, MEK1/2, JNK1/2; phosphorylation assays in HASM cells","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic dissection of signaling pathway, multiple orthogonal methods, single lab","pmids":["20025870"],"is_preprint":false}],"current_model":"ANGPTL4 is a fasting- and lipid-induced secreted glycoprotein regulated transcriptionally by PPARα/γ/δ, HIF-1α, glucocorticoid receptor, NFAT, SMAD3, and other factors; it forms oligomers (essential for activity) that are cleaved by proprotein convertases and inhibit lipoprotein lipase (LPL) by binding overlapping the APOC2 site and promoting irreversible unfolding of LPL's catalytic domain, with ANGPTL8 opposing this by forming ANGPTL4/8 complexes that greatly reduce ANGPTL4's LPL- and EL-inhibitory activity; tissue-specifically, adipose ANGPTL4 mediates fasting-induced LPL suppression and stimulates intracellular lipolysis via cAMP signaling, hepatocyte ANGPTL4 inhibits hepatic lipase, and macrophage/muscle ANGPTL4 serves as a lipid-inducible LPL feedback regulator, while non-metabolic functions include modulation of ferroptosis via TAZ-ANGPTL4-NOX2, macrophage polarization through RORα-mediated induction, AMPK activation in muscle, glucocorticoid-driven ceramide/PP2A/PKCζ insulin resistance, and cell invasion via FMNL2-mediated vesicle trafficking."},"narrative":{"teleology":[{"year":2000,"claim":"Establishing ANGPTL4 as a fasting-induced, PPARα-regulated secreted factor resolved how nutritional state could hormonally control plasma lipid partitioning.","evidence":"Subtractive hybridization in PPARα-null mice with plasma protein detection across fed/fasted states","pmids":["10862772"],"confidence":"High","gaps":["Molecular target of ANGPTL4 in lipid metabolism unknown","Protein structure and processing not characterized"]},{"year":2005,"claim":"Demonstrating that ANGPTL4 directly inhibits LPL in vitro and that its genetic gain/loss of function raises/lowers plasma triglycerides identified LPL as the primary enzymatic target.","evidence":"Purified recombinant protein LPL inhibition assay; transgenic overexpression and targeted gene disruption in mice","pmids":["16081640"],"confidence":"High","gaps":["Mechanism of LPL inactivation unknown","Structural basis of interaction not resolved","Tissue-specific contributions not dissected"]},{"year":2009,"claim":"Revealing that ANGPTL4 oligomerization (but not proteolytic cleavage) is required for LPL inhibition, and that the E40K variant disrupts oligomer stability, connected protein quaternary structure to function and explained a human lipid-lowering variant.","evidence":"Mutagenesis of oligomerization and cleavage sites in HEK-293A cells; LPL activity assays; in vivo mouse validation","pmids":["19270337"],"confidence":"High","gaps":["Structural details of oligomer–LPL interaction not resolved","Whether E40K affects other ANGPTL4 functions unknown"]},{"year":2012,"claim":"Showing that ANGPTL4 stimulates intracellular lipolysis via cAMP signaling downstream of glucocorticoid receptor activation established a second metabolic function beyond extracellular LPL inhibition.","evidence":"Purified human ANGPTL4 added to primary Angptl4−/− adipocytes; cAMP measurement; pharmacological dissection; Angptl4 knockout mice","pmids":["22267746"],"confidence":"High","gaps":["Receptor mediating ANGPTL4-induced cAMP signaling not identified","Relationship between intracellular lipolysis and LPL inhibition unclear"]},{"year":2012,"claim":"Identification of tissue-specific cis-regulatory modules in ANGPTL4 intron 3 and their suppression by microbiota demonstrated how host–microbe interactions regulate lipid metabolism through transcriptional control of ANGPTL4.","evidence":"Transgenic reporter assays in gnotobiotic zebrafish with mutagenesis of regulatory elements","pmids":["22479192"],"confidence":"High","gaps":["Microbial signal and host receptor mediating suppression not identified","Relevance to mammalian intestinal regulation not directly tested"]},{"year":2014,"claim":"Demonstrating that free fatty acids induce ANGPTL4 via PPARδ in non-exercising muscle while AMPK suppresses ANGPTL4 in exercising muscle revealed a metabolic switch directing triglyceride fuel toward active tissue.","evidence":"Human biopsies, animal exercise models, in vitro PPARδ and AMPK manipulation","pmids":["24591600"],"confidence":"High","gaps":["Precise AMPK-mediated transcriptional mechanism not delineated","Whether ANGPTL4 directly activates AMPK or acts indirectly was uncertain"]},{"year":2016,"claim":"Large-scale human exome sequencing established that ANGPTL4 loss-of-function variants (including E40K) lower triglycerides by ~35% and protect against coronary artery disease, validating ANGPTL4 as a therapeutic target.","evidence":"Exome sequencing of 42,930 participants; anti-ANGPTL4 monoclonal antibody in mice and non-human primates","pmids":["26933753","26934567"],"confidence":"High","gaps":["Safety concerns of full ANGPTL4 inhibition (mesenteric lymphadenitis observed in KO mice) not resolved","Contribution of non-LPL functions to cardiovascular protection unknown"]},{"year":2017,"claim":"Elucidating the ANGPTL4→lipolysis→ceramide→PP2A/PKCζ pathway explained how glucocorticoid-induced insulin resistance is mechanistically linked to ANGPTL4-driven adipose lipolysis.","evidence":"Angptl4 knockout mice; metabolomics; PP2A/PKCζ activity assays; ceramide synthesis inhibitors","pmids":["28743803"],"confidence":"High","gaps":["Whether this pathway operates in human glucocorticoid resistance not directly tested","Whether ANGPTL4-driven ceramide signaling contributes to other insulin-resistant states unknown"]},{"year":2018,"claim":"Tissue-specific knockouts of ANGPTL4 in white and brown adipose tissue independently showed enhanced LPL activity, improved glucose tolerance, and metabolic benefits, dissecting the adipose-autonomous contributions of ANGPTL4.","evidence":"Adipose-specific and BAT-specific Angptl4 knockout mice with LPL activity, insulin signaling, and thermogenesis readouts","pmids":["29563332","29627378"],"confidence":"High","gaps":["How adipose ANGPTL4 coordinates with hepatic and macrophage ANGPTL4 in vivo not fully resolved","Long-term consequences of tissue-specific deletion not studied"]},{"year":2020,"claim":"Quantitative reconstitution showed that ANGPTL4/8 complex formation reduces LPL-inhibitory activity >100-fold, providing the molecular basis for insulin-mediated redirection of fatty acids toward adipose storage in the fed state.","evidence":"Recombinant protein LPL inhibition assays; immunoassays in human serum; hepatocyte/adipocyte insulin treatment","pmids":["32487544"],"confidence":"High","gaps":["Structure of the ANGPTL4/8 complex not determined","Stoichiometry and kinetics of complex formation in vivo not quantified"]},{"year":2020,"claim":"Human fasting studies confirmed that ANGPTL4 protein rises in subcutaneous adipose tissue coincident with LPL activity decline without changes in LPL protein, validating ANGPTL4 as the post-translational LPL regulator during fasting in humans.","evidence":"Prospective human adipose biopsies before/after 26-h fast; cortisol/FFA/insulin treatment of primary human adipocytes","pmids":["32504883"],"confidence":"High","gaps":["Whether visceral adipose behaves identically not assessed","Quantitative relationship between ANGPTL4 protein level and LPL inactivation rate in humans not established"]},{"year":2020,"claim":"Hematopoietic ANGPTL4 deficiency was shown to promote myeloid expansion, foam cell formation, and atherosclerosis via increased CD36 and reduced ABCA1, establishing a macrophage-intrinsic anti-atherogenic role distinct from systemic lipid lowering.","evidence":"Bone marrow transplantation in atherosclerosis-prone mice; flow cytometry; CD36/ABCA1 localization assays","pmids":["27460411"],"confidence":"High","gaps":["Direct mechanism linking ANGPTL4 to ABCA1 surface localization not defined","Whether macrophage ANGPTL4 acts through LPL or a separate pathway not fully resolved"]},{"year":2021,"claim":"Hepatocyte-specific ANGPTL4 deletion revealed a liver-autonomous function: inhibition of hepatic lipase (not LPL), controlling remnant lipoprotein catabolism and hepatic fatty acid oxidation.","evidence":"Hepatocyte-specific Angptl4 knockout mice; hepatic lipase activity assays; antisense inhibition; AMPK activation assays","pmids":["34255741"],"confidence":"High","gaps":["Structural basis of ANGPTL4–hepatic lipase interaction unknown","Whether hepatic ANGPTL4 also inhibits LPL in liver endothelium not excluded"]},{"year":2022,"claim":"Large-scale human genetic mimicry analysis confirmed that ANGPTL4's effect on plasma lipids in humans operates exclusively through LPL, not hepatic lipase or endothelial lipase, despite in vitro evidence of EL/HL inhibition.","evidence":"Genetic mimicry analysis across >110,000 UK Biobank participants validated in 11 European populations","pmids":["36372100"],"confidence":"High","gaps":["Whether tissue-specific HL/EL inhibition has local effects not captured by plasma lipid measurements remains possible","Rare variant effects on non-LPL lipases not powered"]},{"year":2023,"claim":"HDX-MS mapping resolved how ANGPTL4 inhibits LPL: it binds overlapping the APOC2 site and destabilizes lid-anchoring structures, promoting irreversible unfolding of the α/β-hydrolase domain — a fundamentally different mechanism from competitive inhibition.","evidence":"Hydrogen-deuterium exchange mass spectrometry; thermal stability assays comparing ANGPTL4 and APOC2 effects on LPL","pmids":["37094117"],"confidence":"High","gaps":["Full atomic-resolution structure of the ANGPTL4–LPL complex not yet available","How oligomeric state of ANGPTL4 modulates unfolding kinetics not determined"]},{"year":2023,"claim":"Identification of FMNL2-dependent actin polymerization at ANGPTL4-containing vesicles (Rab8a+/myosin Vb+) downstream of TGFβ/PKC revealed a regulated secretory trafficking pathway controlling ANGPTL4 release and cancer cell invasion.","evidence":"Super-resolution microscopy; FMNL2 knockdown/phosphorylation mutants; PKC inhibition; invasion assays","pmids":["36691769"],"confidence":"Medium","gaps":["Whether this trafficking pathway operates in non-cancer contexts unknown","Generalizability beyond TGFβ-driven secretion not tested","Single-lab finding"]},{"year":2024,"claim":"Discovery that podocyte/tubule-secreted ANGPTL4 binds Integrin β1 and modulates DPP4–Integrin β1 association to drive STING-mediated fibrogenic signaling expanded ANGPTL4's roles beyond lipid metabolism to kidney fibrosis.","evidence":"Podocyte- and tubule-specific Angptl4 mutant mice; co-IP between ANGPTL4, Integrin β1, DPP4; STING pathway assays; kidney-targeted antisense inhibition","pmids":["39630889"],"confidence":"Medium","gaps":["Structural basis of ANGPTL4–Integrin β1 interaction not determined","Whether this pathway operates in non-diabetic kidney disease unknown","Single-lab finding"]},{"year":null,"claim":"Key unresolved questions include the identity of the receptor mediating ANGPTL4's cAMP-dependent intracellular lipolytic signaling, the full atomic structure of the ANGPTL4 oligomer–LPL complex, and how ANGPTL4's metabolic and non-metabolic (inflammatory, ferroptotic, fibrogenic) functions are coordinated in vivo.","evidence":"","pmids":[],"confidence":"High","gaps":["No receptor identified for ANGPTL4-induced cAMP/lipolysis signaling","No high-resolution structure of full-length ANGPTL4 oligomer bound to LPL","Integration of metabolic and non-metabolic functions in tissue-specific contexts not systematically addressed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,16,18,20,22]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,16,26]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[23]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,3,9,11,12,16,19,21,22]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,9,13,25,30]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[15,27,33]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,5,28,29,31]}],"complexes":["ANGPTL4/8 complex"],"partners":["LPL","ANGPTL8","APOC2","FMNL2","IQGAP1","ITGB1","DPP4"],"other_free_text":[]},"mechanistic_narrative":"ANGPTL4 is a secreted glycoprotein that serves as a central regulator of lipid metabolism by inhibiting lipoprotein lipase (LPL), endothelial lipase, and hepatic lipase in a tissue-specific manner, while also modulating intracellular lipolysis, inflammatory signaling, and cellular redox responses. The protein forms oligomers that are proteolytically cleaved by proprotein convertases; oligomerization of the N-terminal domain is essential for LPL inhibition, which occurs through binding at a site overlapping the APOC2 interface and promoting irreversible unfolding of LPL's catalytic domain [PMID:19270337, PMID:37094117]. ANGPTL8 antagonizes ANGPTL4 by forming ANGPTL4/8 complexes with >100-fold reduced LPL-inhibitory potency, providing a fed-state mechanism to redirect fatty acids toward adipose storage [PMID:32487544]. Transcriptionally regulated by PPARα/γ/δ, glucocorticoid receptor, HIF-1α/TAZ, NFAT, and SMAD3, ANGPTL4 integrates metabolic and inflammatory cues: in adipose tissue it mediates fasting-induced LPL suppression and glucocorticoid-driven lipolysis that raises hepatic ceramide synthesis to impair insulin signaling; in macrophages it regulates foam cell formation and monocyte differentiation; and human loss-of-function variants confer lower triglycerides and protection from coronary artery disease [PMID:22267746, PMID:28743803, PMID:27460411, PMID:26933753]."},"prefetch_data":{"uniprot":{"accession":"Q9BY76","full_name":"Angiopoietin-related protein 4","aliases":["Angiopoietin-like protein 4","Hepatic fibrinogen/angiopoietin-related protein","HFARP"],"length_aa":406,"mass_kda":45.2,"function":"Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:19270337, PubMed:21398697, PubMed:27929370, PubMed:29899144). May also play a role in regulating glucose homeostasis and insulin sensitivity (Probable). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage (PubMed:14583458, PubMed:17068295). Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro) (PubMed:17068295). Depending on context, may modulate tumor-related angiogenesis (By similarity) Mediates inactivation of the lipoprotein lipase LPL, and thereby plays an important role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:19270337, PubMed:21398697, PubMed:27929370, PubMed:29899144). Has higher activity in LPL inactivation than the uncleaved protein (PubMed:19270337, PubMed:21398697)","subcellular_location":"Secreted; Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q9BY76/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ANGPTL4","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ANGPTL4","total_profiled":1310},"omim":[{"mim_id":"618517","title":"ANGIOPOIETIN-LIKE 7; ANGPTL7","url":"https://www.omim.org/entry/618517"},{"mim_id":"615881","title":"PLASMA TRIGLYCERIDE LEVEL QUANTITATIVE TRAIT LOCUS; TGQTL","url":"https://www.omim.org/entry/615881"},{"mim_id":"609336","title":"ANGIOPOIETIN-LIKE 6; ANGPTL6","url":"https://www.omim.org/entry/609336"},{"mim_id":"605910","title":"ANGIOPOIETIN-LIKE 4; ANGPTL4","url":"https://www.omim.org/entry/605910"},{"mim_id":"604815","title":"LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY B, MEMBER 2; LILRB2","url":"https://www.omim.org/entry/604815"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":188.0},{"tissue":"breast","ntpm":162.4},{"tissue":"liver","ntpm":176.8}],"url":"https://www.proteinatlas.org/search/ANGPTL4"},"hgnc":{"alias_symbol":["pp1158","PGAR","ARP4","HFARP","FIAF","NL2"],"prev_symbol":[]},"alphafold":{"accession":"Q9BY76","domains":[{"cath_id":"3.90.215.10","chopping":"189-400","consensus_level":"medium","plddt":94.3231,"start":189,"end":400},{"cath_id":"1.20.5","chopping":"111-143","consensus_level":"medium","plddt":77.3409,"start":111,"end":143}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BY76","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BY76-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BY76-F1-predicted_aligned_error_v6.png","plddt_mean":78.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ANGPTL4","jax_strain_url":"https://www.jax.org/strain/search?query=ANGPTL4"},"sequence":{"accession":"Q9BY76","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BY76.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BY76/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BY76"}},"corpus_meta":[{"pmid":"10862772","id":"PMC_10862772","title":"Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10862772","citation_count":475,"is_preprint":false},{"pmid":"26934567","id":"PMC_26934567","title":"Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.","date":"2016","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26934567","citation_count":412,"is_preprint":false},{"pmid":"26933753","id":"PMC_26933753","title":"Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.","date":"2016","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26933753","citation_count":412,"is_preprint":false},{"pmid":"16081640","id":"PMC_16081640","title":"Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism.","date":"2005","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16081640","citation_count":362,"is_preprint":false},{"pmid":"31641008","id":"PMC_31641008","title":"A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31641008","citation_count":256,"is_preprint":false},{"pmid":"24397894","id":"PMC_24397894","title":"Regulation of lipoprotein lipase by Angptl4.","date":"2014","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/24397894","citation_count":164,"is_preprint":false},{"pmid":"28182091","id":"PMC_28182091","title":"Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway.","date":"2017","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/28182091","citation_count":137,"is_preprint":false},{"pmid":"32487544","id":"PMC_32487544","title":"Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.","date":"2020","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/32487544","citation_count":132,"is_preprint":false},{"pmid":"32205586","id":"PMC_32205586","title":"ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis.","date":"2020","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/32205586","citation_count":122,"is_preprint":false},{"pmid":"34801488","id":"PMC_34801488","title":"Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/34801488","citation_count":113,"is_preprint":false},{"pmid":"29563332","id":"PMC_29563332","title":"Absence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29563332","citation_count":113,"is_preprint":false},{"pmid":"24591600","id":"PMC_24591600","title":"Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24591600","citation_count":113,"is_preprint":false},{"pmid":"19270337","id":"PMC_19270337","title":"Genetic variation in ANGPTL4 provides insights into protein processing and function.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19270337","citation_count":112,"is_preprint":false},{"pmid":"10436015","id":"PMC_10436015","title":"The nuclear actin-related protein of Saccharomyces cerevisiae, Act3p/Arp4, interacts with core histones.","date":"1999","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/10436015","citation_count":107,"is_preprint":false},{"pmid":"24173241","id":"PMC_24173241","title":"Role of Angptl4 in vascular permeability and inflammation.","date":"2013","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/24173241","citation_count":106,"is_preprint":false},{"pmid":"20798332","id":"PMC_20798332","title":"Hypothalamic Angptl4/Fiaf is a novel regulator of food intake and body weight.","date":"2010","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/20798332","citation_count":98,"is_preprint":false},{"pmid":"29627378","id":"PMC_29627378","title":"Brown adipose tissue derived ANGPTL4 controls glucose and lipid metabolism and regulates thermogenesis.","date":"2018","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29627378","citation_count":97,"is_preprint":false},{"pmid":"30814490","id":"PMC_30814490","title":"RREB1-induced upregulation of the lncRNA AGAP2-AS1 regulates the proliferation and migration of pancreatic cancer partly through suppressing ANKRD1 and ANGPTL4.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30814490","citation_count":95,"is_preprint":false},{"pmid":"22267746","id":"PMC_22267746","title":"Angiopoietin-like 4 (Angptl4) protein is a physiological mediator of intracellular lipolysis in murine adipocytes.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22267746","citation_count":94,"is_preprint":false},{"pmid":"34255741","id":"PMC_34255741","title":"Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34255741","citation_count":92,"is_preprint":false},{"pmid":"31434807","id":"PMC_31434807","title":"Antiinflammatory activity of ANGPTL4 facilitates macrophage polarization to induce cardiac repair.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31434807","citation_count":88,"is_preprint":false},{"pmid":"27460411","id":"PMC_27460411","title":"ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27460411","citation_count":87,"is_preprint":false},{"pmid":"25727991","id":"PMC_25727991","title":"Silencing Angiopoietin-Like Protein 4 (ANGPTL4) Protects Against Lipopolysaccharide-Induced Acute Lung Injury Via Regulating SIRT1 /NF-kB Pathway.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25727991","citation_count":75,"is_preprint":false},{"pmid":"23518684","id":"PMC_23518684","title":"ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells utilizes independent pathways.","date":"2013","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23518684","citation_count":73,"is_preprint":false},{"pmid":"31931117","id":"PMC_31931117","title":"Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/31931117","citation_count":68,"is_preprint":false},{"pmid":"30120252","id":"PMC_30120252","title":"The Arp8 and Arp4 module acts as a DNA sensor controlling INO80 chromatin remodeling.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30120252","citation_count":64,"is_preprint":false},{"pmid":"28894280","id":"PMC_28894280","title":"Hypoxia-induced ANGPTL4 sustains tumour growth and anoikis resistance through different mechanisms in scirrhous gastric cancer cell lines.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28894280","citation_count":57,"is_preprint":false},{"pmid":"32504883","id":"PMC_32504883","title":"Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue.","date":"2020","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32504883","citation_count":56,"is_preprint":false},{"pmid":"20664963","id":"PMC_20664963","title":"Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion.","date":"2010","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/20664963","citation_count":56,"is_preprint":false},{"pmid":"32641980","id":"PMC_32641980","title":"Oleic acid-induced NOX4 is dependent on ANGPTL4 expression to promote human colorectal cancer metastasis.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32641980","citation_count":54,"is_preprint":false},{"pmid":"37300585","id":"PMC_37300585","title":"Dual role of ANGPTL4 in inflammation.","date":"2023","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/37300585","citation_count":52,"is_preprint":false},{"pmid":"29490644","id":"PMC_29490644","title":"Increased plasma and adipose tissue levels of ANGPTL8/Betatrophin and ANGPTL4 in people with hypertension.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29490644","citation_count":46,"is_preprint":false},{"pmid":"28743803","id":"PMC_28743803","title":"The glucocorticoid-Angptl4-ceramide axis induces insulin resistance through PP2A and PKCζ.","date":"2017","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/28743803","citation_count":44,"is_preprint":false},{"pmid":"29713054","id":"PMC_29713054","title":"Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29713054","citation_count":43,"is_preprint":false},{"pmid":"29193797","id":"PMC_29193797","title":"The long non-coding RNA PVT1 represses ANGPTL4 transcription through binding with EZH2 in trophoblast cell.","date":"2017","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29193797","citation_count":43,"is_preprint":false},{"pmid":"22573825","id":"PMC_22573825","title":"Heterocomplex formation by Arp4 and β-actin is involved in the integrity of the Brg1 chromatin remodeling complex.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22573825","citation_count":41,"is_preprint":false},{"pmid":"35285130","id":"PMC_35285130","title":"ANGPTL4 regulate glutamine metabolism and fatty acid oxidation in nonsmall cell lung cancer cells.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35285130","citation_count":41,"is_preprint":false},{"pmid":"28972886","id":"PMC_28972886","title":"Paeoniflorin ameliorates Adriamycin-induced nephrotic syndrome through the PPARγ/ANGPTL4 pathway in vivo and vitro.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28972886","citation_count":41,"is_preprint":false},{"pmid":"27166634","id":"PMC_27166634","title":"ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway.","date":"2016","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/27166634","citation_count":40,"is_preprint":false},{"pmid":"22479192","id":"PMC_22479192","title":"Intronic cis-regulatory modules mediate tissue-specific and microbial control of angptl4/fiaf transcription.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22479192","citation_count":37,"is_preprint":false},{"pmid":"21212665","id":"PMC_21212665","title":"Angiopoietin-like 4 (ANGPTL4) gene polymorphisms and risk of brain arteriovenous malformations.","date":"2011","source":"Cerebrovascular diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/21212665","citation_count":37,"is_preprint":false},{"pmid":"33846453","id":"PMC_33846453","title":"Regulation of plasma triglyceride partitioning by adipose-derived ANGPTL4 in mice.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33846453","citation_count":36,"is_preprint":false},{"pmid":"11937627","id":"PMC_11937627","title":"Correlation between chromatin association and transcriptional regulation for the Act3p/Arp4 nuclear actin-related protein of Saccharomyces cerevisiae.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/11937627","citation_count":35,"is_preprint":false},{"pmid":"36638713","id":"PMC_36638713","title":"Eucommia bark/leaf extract improves HFD-induced lipid metabolism disorders via targeting gut microbiota to activate the Fiaf-LPL gut-liver axis and SCFAs-GPR43 gut-fat axis.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36638713","citation_count":35,"is_preprint":false},{"pmid":"36782020","id":"PMC_36782020","title":"ANGPTL4 stabilizes atherosclerotic plaques and modulates the phenotypic transition of vascular smooth muscle cells through KLF4 downregulation.","date":"2023","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36782020","citation_count":34,"is_preprint":false},{"pmid":"32859692","id":"PMC_32859692","title":"Secreted Factors from Adipose Tissue Reprogram Tumor Lipid Metabolism and Induce Motility by Modulating PPARα/ANGPTL4 and FAK.","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/32859692","citation_count":34,"is_preprint":false},{"pmid":"36795484","id":"PMC_36795484","title":"Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36795484","citation_count":33,"is_preprint":false},{"pmid":"22729570","id":"PMC_22729570","title":"AKT3, ANGPTL4, eNOS3, and VEGFA associations with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau.","date":"2012","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/22729570","citation_count":33,"is_preprint":false},{"pmid":"15483052","id":"PMC_15483052","title":"BAF53/Arp4 homolog Alp5 in fission yeast is required for histone H4 acetylation, kinetochore-spindle attachment, and gene silencing at centromere.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15483052","citation_count":32,"is_preprint":false},{"pmid":"26621734","id":"PMC_26621734","title":"Angptl4 links α-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26621734","citation_count":31,"is_preprint":false},{"pmid":"34820432","id":"PMC_34820432","title":"The Pathogenic Role of Long Non-coding RNA H19 in Atherosclerosis via the miR-146a-5p/ANGPTL4 Pathway.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34820432","citation_count":31,"is_preprint":false},{"pmid":"28110976","id":"PMC_28110976","title":"Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma.","date":"2017","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28110976","citation_count":30,"is_preprint":false},{"pmid":"32638512","id":"PMC_32638512","title":"ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a.","date":"2020","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32638512","citation_count":29,"is_preprint":false},{"pmid":"38643448","id":"PMC_38643448","title":"Adipose-derived stem cells promote glycolysis and peritoneal metastasis via TGF-β1/SMAD3/ANGPTL4 axis in colorectal cancer.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38643448","citation_count":28,"is_preprint":false},{"pmid":"29928895","id":"PMC_29928895","title":"HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway.","date":"2018","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/29928895","citation_count":28,"is_preprint":false},{"pmid":"17452364","id":"PMC_17452364","title":"Actin-related protein Arp4 functions in kinetochore assembly.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17452364","citation_count":27,"is_preprint":false},{"pmid":"25060575","id":"PMC_25060575","title":"ANGPTL4 regulates the metastatic potential of oral squamous cell carcinoma.","date":"2014","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25060575","citation_count":27,"is_preprint":false},{"pmid":"26893686","id":"PMC_26893686","title":"Regulation and clinical significance of the hypoxia-induced expression of ANGPTL4 in gastric cancer.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26893686","citation_count":26,"is_preprint":false},{"pmid":"27004807","id":"PMC_27004807","title":"ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels and predicts cardiovascular disease risk in Type 2 diabetic Tunisian population.","date":"2016","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/27004807","citation_count":25,"is_preprint":false},{"pmid":"34311032","id":"PMC_34311032","title":"ANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34311032","citation_count":24,"is_preprint":false},{"pmid":"34405010","id":"PMC_34405010","title":"DNA methylation mediated down-regulation of ANGPTL4 promotes colorectal cancer metastasis by activating the ERK pathway.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34405010","citation_count":24,"is_preprint":false},{"pmid":"38346487","id":"PMC_38346487","title":"Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/38346487","citation_count":23,"is_preprint":false},{"pmid":"39630889","id":"PMC_39630889","title":"Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/39630889","citation_count":23,"is_preprint":false},{"pmid":"32686149","id":"PMC_32686149","title":"Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway.","date":"2020","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32686149","citation_count":23,"is_preprint":false},{"pmid":"34504977","id":"PMC_34504977","title":"Angiopoietin-like protein 4 (ANGPTL4) is an inhibitor of endothelial lipase (EL) while the ANGPTL4/8 complex has reduced EL-inhibitory activity.","date":"2021","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/34504977","citation_count":23,"is_preprint":false},{"pmid":"22307217","id":"PMC_22307217","title":"Mechanisms involved in biological behavior changes associated with Angptl4 expression in colon cancer cell lines.","date":"2012","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22307217","citation_count":23,"is_preprint":false},{"pmid":"26439630","id":"PMC_26439630","title":"Lactobacillus rhamnosus CNCMI-4317 Modulates Fiaf/Angptl4 in Intestinal Epithelial Cells and Circulating Level in Mice.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26439630","citation_count":22,"is_preprint":false},{"pmid":"24659626","id":"PMC_24659626","title":"Promising role of ANGPTL4 gene in diabetic wound healing.","date":"2014","source":"The international journal of lower extremity wounds","url":"https://pubmed.ncbi.nlm.nih.gov/24659626","citation_count":22,"is_preprint":false},{"pmid":"32231436","id":"PMC_32231436","title":"ANGPTL4 Promotes the Proliferation of Papillary Thyroid Cancer via AKT Pathway.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32231436","citation_count":22,"is_preprint":false},{"pmid":"32051864","id":"PMC_32051864","title":"Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells.","date":"2020","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/32051864","citation_count":22,"is_preprint":false},{"pmid":"20025870","id":"PMC_20025870","title":"Induction of ANGPTL4 expression in human airway smooth muscle cells by PMA through activation of PKC and MAPK pathways.","date":"2009","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20025870","citation_count":22,"is_preprint":false},{"pmid":"40383129","id":"PMC_40383129","title":"Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.","date":"2025","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/40383129","citation_count":22,"is_preprint":false},{"pmid":"39647634","id":"PMC_39647634","title":"Cancer-associated fibroblasts regulate mitochondrial metabolism and inhibit chemosensitivity via ANGPTL4-IQGAP1 axis in prostate cancer.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/39647634","citation_count":21,"is_preprint":false},{"pmid":"35210411","id":"PMC_35210411","title":"Single-cell analysis of skin immune cells reveals an Angptl4-ifi20b axis that regulates monocyte differentiation during wound healing.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35210411","citation_count":21,"is_preprint":false},{"pmid":"36372100","id":"PMC_36372100","title":"Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the ANGPTL3-ANGPTL8 Complex and ANGPTL4.","date":"2022","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/36372100","citation_count":21,"is_preprint":false},{"pmid":"32500296","id":"PMC_32500296","title":"Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the \"Prime Time\" of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?","date":"2021","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32500296","citation_count":21,"is_preprint":false},{"pmid":"29952246","id":"PMC_29952246","title":"Role of Angptl4/Fiaf in exercise-induced skeletal muscle AMPK activation.","date":"2018","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/29952246","citation_count":20,"is_preprint":false},{"pmid":"35860030","id":"PMC_35860030","title":"ANGPTL4 Regulates Psoriasis via Modulating Hyperproliferation and Inflammation of Keratinocytes.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35860030","citation_count":20,"is_preprint":false},{"pmid":"27505034","id":"PMC_27505034","title":"The downregulation of ANGPTL4 inhibits the migration and proliferation of tongue squamous cell carcinoma.","date":"2016","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/27505034","citation_count":20,"is_preprint":false},{"pmid":"32132651","id":"PMC_32132651","title":"MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32132651","citation_count":19,"is_preprint":false},{"pmid":"39392008","id":"PMC_39392008","title":"Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/39392008","citation_count":19,"is_preprint":false},{"pmid":"36467503","id":"PMC_36467503","title":"ANGPTL4 Regulates Lung Adenocarcinoma Pyroptosis and Apoptosis via NLRP3\\ASC\\Caspase 8 Signaling Pathway to Promote Resistance to Gefitinib.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36467503","citation_count":19,"is_preprint":false},{"pmid":"30911775","id":"PMC_30911775","title":"PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4.","date":"2019","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/30911775","citation_count":18,"is_preprint":false},{"pmid":"34571076","id":"PMC_34571076","title":"Nickel chloride regulates ANGPTL4 via the HIF-1α-mediated TET1 expression in lung cells.","date":"2021","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34571076","citation_count":18,"is_preprint":false},{"pmid":"37094117","id":"PMC_37094117","title":"Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37094117","citation_count":18,"is_preprint":false},{"pmid":"34396783","id":"PMC_34396783","title":"Chronic high-fat feeding and prolonged fasting in liver-specific ANGPTL4 knockout mice.","date":"2021","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34396783","citation_count":18,"is_preprint":false},{"pmid":"35843572","id":"PMC_35843572","title":"ANGPTL4 attenuates palmitic acid-induced endothelial cell injury by increasing autophagy.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35843572","citation_count":17,"is_preprint":false},{"pmid":"36607250","id":"PMC_36607250","title":"ANGPTL4 inhibits granulosa cell proliferation in polycystic ovary syndrome by EGFR/JAK1/STAT3-mediated induction of p21.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/36607250","citation_count":16,"is_preprint":false},{"pmid":"32623702","id":"PMC_32623702","title":"Danlou Tablet Improves Chronic Intermittent Hypoxia-Induced Dyslipidemia and Arteriosclerosis by HIF-1α-Angptl4 mRNA Signaling Pathway.","date":"2020","source":"Chinese journal of integrative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32623702","citation_count":16,"is_preprint":false},{"pmid":"31428774","id":"PMC_31428774","title":"PPARβ/δ recruits NCOR and regulates transcription reinitiation of ANGPTL4.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31428774","citation_count":16,"is_preprint":false},{"pmid":"34422410","id":"PMC_34422410","title":"ANGPTL4 Attenuates Ang II-Induced Atrial Fibrillation and Fibrosis in Mice via PPAR Pathway.","date":"2021","source":"Cardiology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/34422410","citation_count":16,"is_preprint":false},{"pmid":"36994700","id":"PMC_36994700","title":"STAT2-induced linc02231 promotes tumorigenesis and angiogenesis through modulation of hnRNPA1/ANGPTL4 in colorectal cancer.","date":"2023","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36994700","citation_count":15,"is_preprint":false},{"pmid":"32084431","id":"PMC_32084431","title":"Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals.","date":"2020","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/32084431","citation_count":15,"is_preprint":false},{"pmid":"39633372","id":"PMC_39633372","title":"SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes.","date":"2024","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/39633372","citation_count":14,"is_preprint":false},{"pmid":"32204557","id":"PMC_32204557","title":"The Actin-Family Protein Arp4 Is a Novel Suppressor for the Formation and Functions of Nuclear F-Actin.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32204557","citation_count":14,"is_preprint":false},{"pmid":"36691769","id":"PMC_36691769","title":"Vesicle-Associated Actin Assembly by Formins Promotes TGFβ-Induced ANGPTL4 Trafficking, Secretion and Cell Invasion.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36691769","citation_count":14,"is_preprint":false},{"pmid":"36402848","id":"PMC_36402848","title":"ANGPTL4, IL-6 and TNF-α as regulators of lipid metabolism during a marathon run.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36402848","citation_count":14,"is_preprint":false},{"pmid":"32194081","id":"PMC_32194081","title":"EZH2 inhibition promotes ANGPTL4/CREB1 to suppress the progression of ulcerative colitis.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32194081","citation_count":14,"is_preprint":false},{"pmid":"37290266","id":"PMC_37290266","title":"HIF-1α regulates osteoclastogenesis and alveolar bone resorption in periodontitis via ANGPTL4.","date":"2023","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/37290266","citation_count":14,"is_preprint":false},{"pmid":"32114885","id":"PMC_32114885","title":"Aberrant hydroxymethylation of ANGPTL4 is associated with selective intrauterine growth restriction in monochorionic twin pregnancies.","date":"2020","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/32114885","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":58111,"output_tokens":8652,"usd":0.152057},"stage2":{"model":"claude-opus-4-6","input_tokens":12625,"output_tokens":4116,"usd":0.249037},"total_usd":0.401094,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"ANGPTL4 (FIAF) is a PPARα target gene identified by subtractive hybridization; it is predominantly expressed in adipose tissue, secreted into blood plasma, and plasma levels increase with fasting and decrease with chronic high-fat feeding, establishing its role as a fasting-regulated endocrine factor.\",\n      \"method\": \"Subtractive hybridization (SABRE), mRNA quantification, plasma protein detection across wild-type and PPARα-null mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational discovery using multiple methods in genetic knockout model, replicated across tissues\",\n      \"pmids\": [\"10862772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Recombinant ANGPTL4 protein directly inhibits LPL activity in vitro; transgenic overexpression of human ANGPTL4 in liver elevates plasma triglycerides and reduces post-heparin LPL activity, while ANGPTL4-deficient mice show hypotriglyceridemia and increased LPL activity, with greater effect in the fasted state.\",\n      \"method\": \"In vitro LPL inhibition assay with purified recombinant protein; transgenic overexpression; targeted gene disruption in mice; post-heparin plasma LPL activity measurement\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution plus complementary genetic gain- and loss-of-function mouse models\",\n      \"pmids\": [\"16081640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ANGPTL4 forms dimers and tetramers intracellularly before secretion; it is cleaved by a proprotein convertase at RRKR(164), releasing an oligomeric N-terminal domain and monomeric C-terminal fibrinogen-like domain. Oligomerization, but not cleavage, is required for LPL inhibition. The E40K variant is synthesized and processed normally but N-terminal oligomers fail to accumulate extracellularly, abolishing LPL inhibition.\",\n      \"method\": \"Expression in HEK-293A cells; mutagenesis of oligomerization and cleavage sites; LPL activity assays; in vivo validation in mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus in vitro enzymatic assay, validated in vivo\",\n      \"pmids\": [\"19270337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ANGPTL4 mediates fasting-induced intracellular lipolysis in white adipose tissue downstream of glucocorticoid receptor activation; ANGPTL4 stimulates cAMP signaling upstream of adenylate cyclase and downstream of receptor activation in adipocytes, and purified human ANGPTL4 alone is sufficient to increase cAMP and induce lipolysis in primary Angptl4−/− adipocytes.\",\n      \"method\": \"Angptl4 knockout mice; glucocorticoid receptor blockade; primary adipocyte treatment with purified human ANGPTL4; cAMP measurement; phosphorylation of lipolytic enzymes; pharmacological dissection of signaling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — purified protein reconstitution in knockout cells, multiple pharmacological probes, in vivo confirmation\",\n      \"pmids\": [\"22267746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Tissue-specific cis-regulatory modules within angptl4 intron 3 drive expression in liver, pancreatic islet β-cells, and intestinal enterocytes in zebrafish; the microbiota suppresses the transcriptional activity of the intestine-specific regulatory module, thereby reducing intestinal Angptl4 expression.\",\n      \"method\": \"Transgenic reporter assays in zebrafish; gnotobiotic colonization; site-directed mutagenesis of regulatory sequences; comparative sequence analysis across 12 teleost species\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo transgenic reporters with mutagenesis and gnotobiotic functional validation\",\n      \"pmids\": [\"22479192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Butyrate induces intestinal ANGPTL4 expression via a PPARγ-independent, butyrate-responsive element ~0.5 kb upstream of the transcription start site, while PPARγ ligands act on a downstream PPAR-responsive element; these two pathways are additive.\",\n      \"method\": \"RT-PCR; promoter dissection; PPARγ inhibitor and siRNA experiments; germ-free mouse colonization with Clostridium tyrobutyricum; butyrate gavage\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological dissection of two independent promoter elements, validated in germ-free mice\",\n      \"pmids\": [\"23518684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In non-exercising muscle during acute exercise, ANGPTL4 is induced by elevated plasma free fatty acids via PPARδ activation; in exercising muscle, ANGPTL4 induction is counteracted by AMPK-mediated downregulation, promoting local triglyceride uptake as fuel.\",\n      \"method\": \"Human biopsy studies; animal exercise models; in vitro PPARδ and AMPK manipulation; combination of human, animal, and cell data\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multi-level (human/animal/cell) orthogonal data demonstrating FFA-PPARδ induction and AMPK-mediated suppression\",\n      \"pmids\": [\"24591600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Adipose-derived Angptl4 links glucagon receptor antagonist-induced adipose triglyceride metabolism to α-cell proliferation; Angptl4 is upregulated via PPARγ activation in white adipose tissue following glucagon receptor antagonist treatment, and Angptl4 supplementation specifically promotes α-cell proliferation, while Angptl4 knockout mice treated with glucagon receptor antagonist do not show increased glucagon or α-cell proliferation.\",\n      \"method\": \"Angptl4 knockout mice; glucagon receptor antagonist treatment; Angptl4 protein supplementation; pancreatic α-cell quantification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO epistasis combined with protein supplementation rescue and defined cellular readout\",\n      \"pmids\": [\"26621734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ANGPTL4 loss-of-function mutations in humans (including E40K) are associated with 35% lower triglyceride levels and protection from coronary artery disease; monoclonal antibody inhibition of Angptl4 in mice and monkeys reduces triglyceride levels, confirming LPL inhibition as the functional mechanism.\",\n      \"method\": \"Exome sequencing of 42,930 participants; genetic association study; anti-ANGPTL4 monoclonal antibody in mice and non-human primates; lipid measurements\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large-scale human genetics corroborated by pharmacological inhibition in two animal species\",\n      \"pmids\": [\"26933753\", \"26934567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Glucocorticoid-induced insulin resistance is mediated by Angptl4: Angptl4 stimulates lipolysis in white adipose tissue, raising fatty acid flux to the liver and increasing hepatic ceramide synthesis via ceramide synthetic enzymes. Ceramide then activates PP2A and PKCζ to impair insulin signaling. Pharmacological inhibition of ceramide synthesis or PKCζ rescued glucose intolerance in wild-type but not Angptl4-null mice.\",\n      \"method\": \"Angptl4 knockout mice; metabolomic profiling; PP2A and PKCζ activity assays; ceramide synthesis inhibitors; genetic epistasis\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — metabolomics, enzymatic assays, pharmacological and genetic epistasis across multiple orthogonal methods\",\n      \"pmids\": [\"28743803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structures of the fibrinogen-like domains of ANGPTL4 (and ANGPTL3) were solved, providing structural insights into loss-of-function mutation sites and potential mechanisms of LPL interaction.\",\n      \"method\": \"X-ray crystallography of fibrinogen-like domain\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure, but functional validation is limited and primarily structural insight\",\n      \"pmids\": [\"29713054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Adipose tissue-specific deletion of ANGPTL4 results in enhanced LPL activity, rapid clearance of circulating TAGs, increased adipose lipolysis and fatty acid oxidation, decreased hepatic ectopic lipid deposition, reduced nPKC membrane translocation, improved insulin signaling, improved glucose tolerance, and attenuated atherosclerosis in high-fat diet-fed mice.\",\n      \"method\": \"Adipose-specific Angptl4 knockout mice; LPL activity assays; metabolic turnover studies; insulin signaling assays; atherosclerosis quantification\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO with multiple defined metabolic and cellular readouts\",\n      \"pmids\": [\"29563332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Brown adipose tissue-specific deletion of ANGPTL4 results in enhanced LPL activity, increased circulating TAG clearance, increased fatty acid oxidation, reduced fatty acid synthesis, improved glucose tolerance, and enhanced thermogenesis during cold exposure.\",\n      \"method\": \"BAT-specific Angptl4 knockout mice; LPL activity assays; fatty acid oxidation and synthesis measurements; cold exposure thermogenesis assay\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO with multiple defined metabolic readouts\",\n      \"pmids\": [\"29627378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In exercising skeletal muscle, Angptl4 treatment activates AMPK signaling (phosphorylation of AMPK and ACC) and increases mitochondrial maximum respiratory capacity; Angptl4-knockout mice show attenuated exercise-induced AMPK phosphorylation and reduced exercise endurance.\",\n      \"method\": \"C2C12 myotube treatment with recombinant Angptl4; Angptl4 knockout mice; treadmill and swimming endurance tests; AMPK/ACC phosphorylation assays\",\n      \"journal\": \"Journal of applied physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct protein treatment in cells combined with KO mouse data, but single lab\",\n      \"pmids\": [\"29952246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TAZ directly regulates ANGPTL4 as a target gene; ANGPTL4 sensitizes ovarian cancer cells to ferroptosis by activating NOX2; TAZ removal confers ferroptosis resistance whereas constitutively active TAZ enhances susceptibility via the ANGPTL4-NOX2 axis.\",\n      \"method\": \"TAZ knockdown and overexpression; ANGPTL4 depletion; NOX2 activity assays; ferroptosis assays in ovarian cancer cell lines; integrative genomic analysis\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistatic genetic dissection with functional ferroptosis readout, single lab\",\n      \"pmids\": [\"31641008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ANGPTL4 from MSCs is induced by RORα in response to inflammatory mediators (IL-1β); RORα binds the ANGPTL4 promoter; ANGPTL4 secreted by MSCs suppresses macrophage polarization toward the pro-inflammatory phenotype, and ANGPTL4-deficient MSCs fail to inhibit inflammatory macrophage polarization.\",\n      \"method\": \"MSC-macrophage co-culture; ANGPTL4-deficient MSC generation; ChIP demonstrating RORα binding to ANGPTL4 promoter; peritonitis and myocardial infarction animal models\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, KO MSC epistasis, in vivo model, single lab\",\n      \"pmids\": [\"31434807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ANGPTL8 forms complexes with ANGPTL4, and the ANGPTL4/8 complex has >100-fold reduced LPL-inhibitory activity compared to ANGPTL4 alone; conversely ANGPTL3/8 has >100-fold increased LPL-inhibitory activity vs ANGPTL3 alone. Insulin increases ANGPTL4/8 secretion from adipocytes, which during feeding blocks ANGPTL4-mediated LPL inhibition in adipose tissue, directing fatty acids toward fat storage.\",\n      \"method\": \"Quantitative LPL inhibition assays with recombinant proteins and complexes; immunoassay quantification of complexes in human serum; competition experiments; hepatocyte and adipocyte insulin treatment\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — quantitative reconstituted in vitro assay, validated with human serum measurements and cell experiments\",\n      \"pmids\": [\"32487544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Oleic acid induces ANGPTL4 expression in colorectal cancer cells; ANGPTL4 is required for c-Jun-mediated transactivation of NOX4, leading to increased ROS and upregulation of MMP-1 and MMP-9, promoting cancer cell metastasis. ANGPTL4 depletion abrogates oleic acid-induced NOX4 induction and metastatic seeding.\",\n      \"method\": \"ANGPTL4 knockdown; NOX4 transcription assays; ROS measurement; MMP expression; in vitro invasion assays; in vivo tumor extravasation model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockdown epistasis with mechanistic signaling readouts in vitro and in vivo, single lab\",\n      \"pmids\": [\"32641980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ANGPTL4 promotes the unfolding of LPL leading to LPL cleavage and subsequent degradation in adipocytes; ANGPTL8 opposes this by keeping LPL active after feeding. In macrophages and cardiomyocytes, ANGPTL4 acts as a lipid-inducible feedback regulator of LPL-mediated lipid uptake. In hepatocytes, ANGPTL4 functions as a local inhibitor of hepatic lipase.\",\n      \"method\": \"Review integrating mechanistic studies from multiple labs (genetic models, biochemical assays, unfolding experiments)\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — synthesis of replicated biochemical and genetic findings across multiple labs; LPL unfolding mechanism established by structural/biochemical studies\",\n      \"pmids\": [\"34801488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hepatocyte-specific Angptl4 deficiency increases hepatic lipase (HL) activity, facilitating catabolism of TAG-rich lipoprotein remnants in the liver, reducing circulating TAG and cholesterol; it also promotes fatty acid uptake leading to increased fatty acid oxidation, ROS production, and AMPK activation in hepatocytes.\",\n      \"method\": \"Hepatocyte-specific Angptl4 mutant mice; metabolic turnover studies; hepatic lipase activity assays; fatty acid oxidation measurement; AMPK activation assays; liver-targeted antisense inhibition\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific genetic model with multiple mechanistic readouts and pharmacological validation\",\n      \"pmids\": [\"34255741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ANGPTL4 is a more potent inhibitor of endothelial lipase (EL) than ANGPTL3; formation of the ANGPTL4/8 complex markedly reduces ANGPTL4's EL-inhibitory activity, while ANGPTL3/8 complex formation increases EL inhibition compared to ANGPTL3 alone.\",\n      \"method\": \"In vitro recombinant protein EL inhibition assays; comparison of ANGPTL3, ANGPTL4, ANGPTL3/8, and ANGPTL4/8 complex activities\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative in vitro enzymatic assay with purified recombinant proteins\",\n      \"pmids\": [\"34504977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Genetic mimicry analysis in >110,000 individuals demonstrates that ANGPTL4 suppression is highly concordant with LPL enhancement but not with hepatic lipase or EL suppression, indicating ANGPTL4 modulates plasma lipid parameters exclusively via LPL in humans.\",\n      \"method\": \"Human genetic mimicry analysis using UK Biobank (>110,000 subjects) and validation in 11 European populations; variant-level concordance analysis across 248 metabolic parameters\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large-scale human genetic evidence, validated in independent populations with mechanistic specificity\",\n      \"pmids\": [\"36372100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ANGPTL4 inhibits LPL by destabilizing lid-anchoring structures via binding overlapping with the APOC2 binding site on LPL; ANGPTL4 decreases LPL thermal stability and promotes irreversible unfolding of LPL's α/β-hydrolase domain, whereas APOC2 binding to the same region stabilizes LPL and protects it from unfolding.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry (HDX-MS) mapping of binding sites on LPL; thermal stability assays; comparison of ANGPTL4 and APOC2 effects on LPL conformation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — HDX-MS structural mapping with functional thermal stability readouts revealing mechanism of LPL inactivation\",\n      \"pmids\": [\"37094117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TGFβ stimulates ANGPTL4 vesicle trafficking and secretion through formin-like 2 (FMNL2); PKC-dependent phosphorylation of FMNL2 downstream of TGFβ is required; FMNL2 directly polymerizes actin at ANGPTL4-containing vesicles (associated with Rab8a and myosin Vb) to facilitate their mobility and cancer cell invasion.\",\n      \"method\": \"Super-resolution microscopy; FMNL2 knockdown and phosphorylation mutants; PKC inhibition; co-localization studies; actin polymerization assays at vesicles; invasion assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — super-resolution imaging with genetic and pharmacological mechanistic dissection, single lab\",\n      \"pmids\": [\"36691769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ANGPTL4 treatment in atherosclerotic Apoe−/− mice reduces vascular smooth muscle cell (SMC) phenotypic transition to macrophage-like cells by reducing TNFα-induced NOX1 activation, thereby suppressing KLF4 expression and preventing SMC dedifferentiation; this stabilizes atherosclerotic plaques by increasing fibrous cap thickness.\",\n      \"method\": \"ANGPTL4 protein injection in Apoe−/− mice; SMC phenotype assays (α-SMA, SM22α, KLF4, CD68 staining); NOX1 assays; fibrotic cap morphometry\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo protein treatment with mechanistic signaling readouts, single lab\",\n      \"pmids\": [\"36782020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Podocyte- and tubule-secreted ANGPTL4 interacts with Integrin β1 and influences the association between dipeptidyl peptidase-4 (DPP4) and Integrin β1; this interaction drives fibrogenic signaling including STING pathway activation, pro-inflammatory cytokine expression, EMT, and mitochondrial damage in diabetic kidney disease.\",\n      \"method\": \"Podocyte- and tubule-specific Angptl4 mutant mice; diabetes model; co-IP/binding assays between ANGPTL4, Integrin β1, and DPP4; STING pathway assays; kidney-targeted antisense inhibition\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO, binding interaction assays, and pharmacological rescue, single lab\",\n      \"pmids\": [\"39630889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Fasting in humans increases ANGPTL4 mRNA (+90%) and protein (+46%) in subcutaneous adipose tissue coincident with a 60% reduction in adipose LPL activity, without changes in LPL mRNA or protein; cortisol and fatty acids upregulate ANGPTL4 in primary human adipocytes while insulin downregulates it.\",\n      \"method\": \"Human clinical study with adipose biopsies before and after 26-h fast; LPL activity assay; ANGPTL4 mRNA and protein quantification; primary human adipocyte treatment with cortisol, fatty acids, and insulin\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — prospective human biopsy study with multiple molecular readouts, corroborated by primary cell experiments\",\n      \"pmids\": [\"32504883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ANGPTL4 deficiency in haematopoietic cells promotes monocyte/myeloid progenitor expansion and atherosclerosis; macrophage ANGPTL4 deficiency increases CD36 expression and reduces ABCA1 surface localization, promoting foam cell formation; ANGPTL4-deficient common myeloid progenitors have higher lipid raft content and are more proliferative and less apoptotic.\",\n      \"method\": \"Bone marrow transplantation; atherosclerosis quantification; flow cytometry of myeloid progenitors; CD36 and ABCA1 expression and localization assays; lipid raft staining\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — haematopoietic-specific KO with multiple cellular mechanism readouts, published in high-impact journal\",\n      \"pmids\": [\"27460411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PPARβ/δ represses ANGPTL4 transcription in the absence of ligands by recruiting NCOR (identified as the main interactor by mass spectrometry), which reduces recruitment of Mediator subunits, RNA polymerase II, and TFIIB to the ANGPTL4 promoter; this repression is partially HDAC-independent.\",\n      \"method\": \"ChIP assays; mass spectrometry identification of PPARβ/δ interactors; PPARβ/δ mutant reconstitution in KO cells; RNA polymerase II and general transcription factor occupancy assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, MS interactome, and mutant reconstitution, single lab\",\n      \"pmids\": [\"31428774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Calcineurin (CaN) inhibitors reduce ANGPTL4 expression in podocytes via suppression of Nfatc1; ChIP assays demonstrate that Nfatc1 directly binds the Angptl4 promoter and increases its transcription; overexpression of ANGPTL4 in podocytes induces cytoskeletal rearrangement, reduces synaptopodin, and enhances apoptosis.\",\n      \"method\": \"PAN-induced nephrotic syndrome rat model; CaN inhibitor treatment; Nfatc1 overexpression and knockdown; ChIP assays; podocyte cytoskeletal and apoptosis assays\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP showing direct transcription factor binding, genetic overexpression/KD with cellular readouts, single lab\",\n      \"pmids\": [\"32686149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CAF-secreted ANGPTL4 binds to IQGAP1 on prostate cancer cell membranes, activating the Raf-MEK-ERK-PGC1α axis to promote mitochondrial biogenesis and oxidative phosphorylation metabolism, thereby facilitating cancer cell growth and chemoresistance.\",\n      \"method\": \"GST pull-down assay; Co-IP; proteomics of conditioned media; metabolomics; IQGAP1 inhibitor screening; in vitro and in vivo cancer models\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — GST pulldown and Co-IP establishing direct binding, with metabolomics and signaling pathway readouts, single lab\",\n      \"pmids\": [\"39647634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMAD3 (activated by TGF-β1 secreted by adipose-derived stem cells) directly binds to the ANGPTL4 promoter as shown by chromatin immunoprecipitation, upregulating ANGPTL4 transcription in colorectal cancer cells to promote glycolysis and anoikis resistance.\",\n      \"method\": \"ChIP assay; RNA sequencing; co-culture with adipose-derived stem cells; ANGPTL4 knockdown; in vivo peritoneal seeding model\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct transcription factor binding, validated with KD epistasis in vivo, single lab\",\n      \"pmids\": [\"38643448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ANGPTL4/8 complex and the C-terminal domain-containing ANGPTL4 (CD-ANGPTL4) fragment are positively associated with inflammation (CRP), diabetes prevalence, and cardiovascular mortality in two independent large cohorts; ANGPTL3/8 potently inhibits GPIHBP1-bound LPL activity in recombinant protein assays.\",\n      \"method\": \"Recombinant protein LPL activity assay with GPIHBP1; dedicated immunoassays for ANGPTL3/8, ANGPTL4/8, CD-ANGPTL4 in 2394 LURIC and 6188 getABI participants; longitudinal outcome analysis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro enzymatic assay plus large-scale human observational validation, single lab\",\n      \"pmids\": [\"39392008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Angptl4 modulates monocyte-to-macrophage differentiation during wound healing via regulation of interferon activated gene ifi202b; Angptl4-mediated kinome signaling (involving S6K, JAK, CDK) controls ifi202b expression; silencing ifi202b in Angptl4-deficient monocytes rescues impaired monocyte-to-macrophage transition in vitro.\",\n      \"method\": \"Flow cytometry; single-cell RNA sequencing; unbiased kinase inhibitor screen; siRNA rescue experiments; Angptl4 knockout and LysM-specific knockout mice; wound healing models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq, KO models, kinase screen, and siRNA rescue, single lab\",\n      \"pmids\": [\"35210411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Induction of ANGPTL4 expression in airway smooth muscle cells by PKC activators requires activation of the Ras-MEK1/2-ERK1/2 pathway and the JNK pathway, but not the p38 MAPK pathway; knockdown of PKCα, MEK1/2, or JNK1/2 inhibits PMA-induced ANGPTL4 upregulation.\",\n      \"method\": \"PKC inhibitors; specific kinase inhibitors (U0126, SP600125, manumycin A); siRNA knockdown of PKCs, MEK1/2, JNK1/2; phosphorylation assays in HASM cells\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic dissection of signaling pathway, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"20025870\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ANGPTL4 is a fasting- and lipid-induced secreted glycoprotein regulated transcriptionally by PPARα/γ/δ, HIF-1α, glucocorticoid receptor, NFAT, SMAD3, and other factors; it forms oligomers (essential for activity) that are cleaved by proprotein convertases and inhibit lipoprotein lipase (LPL) by binding overlapping the APOC2 site and promoting irreversible unfolding of LPL's catalytic domain, with ANGPTL8 opposing this by forming ANGPTL4/8 complexes that greatly reduce ANGPTL4's LPL- and EL-inhibitory activity; tissue-specifically, adipose ANGPTL4 mediates fasting-induced LPL suppression and stimulates intracellular lipolysis via cAMP signaling, hepatocyte ANGPTL4 inhibits hepatic lipase, and macrophage/muscle ANGPTL4 serves as a lipid-inducible LPL feedback regulator, while non-metabolic functions include modulation of ferroptosis via TAZ-ANGPTL4-NOX2, macrophage polarization through RORα-mediated induction, AMPK activation in muscle, glucocorticoid-driven ceramide/PP2A/PKCζ insulin resistance, and cell invasion via FMNL2-mediated vesicle trafficking.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ANGPTL4 is a secreted glycoprotein that serves as a central regulator of lipid metabolism by inhibiting lipoprotein lipase (LPL), endothelial lipase, and hepatic lipase in a tissue-specific manner, while also modulating intracellular lipolysis, inflammatory signaling, and cellular redox responses. The protein forms oligomers that are proteolytically cleaved by proprotein convertases; oligomerization of the N-terminal domain is essential for LPL inhibition, which occurs through binding at a site overlapping the APOC2 interface and promoting irreversible unfolding of LPL's catalytic domain [PMID:19270337, PMID:37094117]. ANGPTL8 antagonizes ANGPTL4 by forming ANGPTL4/8 complexes with >100-fold reduced LPL-inhibitory potency, providing a fed-state mechanism to redirect fatty acids toward adipose storage [PMID:32487544]. Transcriptionally regulated by PPARα/γ/δ, glucocorticoid receptor, HIF-1α/TAZ, NFAT, and SMAD3, ANGPTL4 integrates metabolic and inflammatory cues: in adipose tissue it mediates fasting-induced LPL suppression and glucocorticoid-driven lipolysis that raises hepatic ceramide synthesis to impair insulin signaling; in macrophages it regulates foam cell formation and monocyte differentiation; and human loss-of-function variants confer lower triglycerides and protection from coronary artery disease [PMID:22267746, PMID:28743803, PMID:27460411, PMID:26933753].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing ANGPTL4 as a fasting-induced, PPARα-regulated secreted factor resolved how nutritional state could hormonally control plasma lipid partitioning.\",\n      \"evidence\": \"Subtractive hybridization in PPARα-null mice with plasma protein detection across fed/fasted states\",\n      \"pmids\": [\"10862772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of ANGPTL4 in lipid metabolism unknown\", \"Protein structure and processing not characterized\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that ANGPTL4 directly inhibits LPL in vitro and that its genetic gain/loss of function raises/lowers plasma triglycerides identified LPL as the primary enzymatic target.\",\n      \"evidence\": \"Purified recombinant protein LPL inhibition assay; transgenic overexpression and targeted gene disruption in mice\",\n      \"pmids\": [\"16081640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of LPL inactivation unknown\", \"Structural basis of interaction not resolved\", \"Tissue-specific contributions not dissected\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealing that ANGPTL4 oligomerization (but not proteolytic cleavage) is required for LPL inhibition, and that the E40K variant disrupts oligomer stability, connected protein quaternary structure to function and explained a human lipid-lowering variant.\",\n      \"evidence\": \"Mutagenesis of oligomerization and cleavage sites in HEK-293A cells; LPL activity assays; in vivo mouse validation\",\n      \"pmids\": [\"19270337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of oligomer–LPL interaction not resolved\", \"Whether E40K affects other ANGPTL4 functions unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showing that ANGPTL4 stimulates intracellular lipolysis via cAMP signaling downstream of glucocorticoid receptor activation established a second metabolic function beyond extracellular LPL inhibition.\",\n      \"evidence\": \"Purified human ANGPTL4 added to primary Angptl4−/− adipocytes; cAMP measurement; pharmacological dissection; Angptl4 knockout mice\",\n      \"pmids\": [\"22267746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating ANGPTL4-induced cAMP signaling not identified\", \"Relationship between intracellular lipolysis and LPL inhibition unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of tissue-specific cis-regulatory modules in ANGPTL4 intron 3 and their suppression by microbiota demonstrated how host–microbe interactions regulate lipid metabolism through transcriptional control of ANGPTL4.\",\n      \"evidence\": \"Transgenic reporter assays in gnotobiotic zebrafish with mutagenesis of regulatory elements\",\n      \"pmids\": [\"22479192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Microbial signal and host receptor mediating suppression not identified\", \"Relevance to mammalian intestinal regulation not directly tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that free fatty acids induce ANGPTL4 via PPARδ in non-exercising muscle while AMPK suppresses ANGPTL4 in exercising muscle revealed a metabolic switch directing triglyceride fuel toward active tissue.\",\n      \"evidence\": \"Human biopsies, animal exercise models, in vitro PPARδ and AMPK manipulation\",\n      \"pmids\": [\"24591600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise AMPK-mediated transcriptional mechanism not delineated\", \"Whether ANGPTL4 directly activates AMPK or acts indirectly was uncertain\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Large-scale human exome sequencing established that ANGPTL4 loss-of-function variants (including E40K) lower triglycerides by ~35% and protect against coronary artery disease, validating ANGPTL4 as a therapeutic target.\",\n      \"evidence\": \"Exome sequencing of 42,930 participants; anti-ANGPTL4 monoclonal antibody in mice and non-human primates\",\n      \"pmids\": [\"26933753\", \"26934567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Safety concerns of full ANGPTL4 inhibition (mesenteric lymphadenitis observed in KO mice) not resolved\", \"Contribution of non-LPL functions to cardiovascular protection unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Elucidating the ANGPTL4→lipolysis→ceramide→PP2A/PKCζ pathway explained how glucocorticoid-induced insulin resistance is mechanistically linked to ANGPTL4-driven adipose lipolysis.\",\n      \"evidence\": \"Angptl4 knockout mice; metabolomics; PP2A/PKCζ activity assays; ceramide synthesis inhibitors\",\n      \"pmids\": [\"28743803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway operates in human glucocorticoid resistance not directly tested\", \"Whether ANGPTL4-driven ceramide signaling contributes to other insulin-resistant states unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Tissue-specific knockouts of ANGPTL4 in white and brown adipose tissue independently showed enhanced LPL activity, improved glucose tolerance, and metabolic benefits, dissecting the adipose-autonomous contributions of ANGPTL4.\",\n      \"evidence\": \"Adipose-specific and BAT-specific Angptl4 knockout mice with LPL activity, insulin signaling, and thermogenesis readouts\",\n      \"pmids\": [\"29563332\", \"29627378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How adipose ANGPTL4 coordinates with hepatic and macrophage ANGPTL4 in vivo not fully resolved\", \"Long-term consequences of tissue-specific deletion not studied\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Quantitative reconstitution showed that ANGPTL4/8 complex formation reduces LPL-inhibitory activity >100-fold, providing the molecular basis for insulin-mediated redirection of fatty acids toward adipose storage in the fed state.\",\n      \"evidence\": \"Recombinant protein LPL inhibition assays; immunoassays in human serum; hepatocyte/adipocyte insulin treatment\",\n      \"pmids\": [\"32487544\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the ANGPTL4/8 complex not determined\", \"Stoichiometry and kinetics of complex formation in vivo not quantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Human fasting studies confirmed that ANGPTL4 protein rises in subcutaneous adipose tissue coincident with LPL activity decline without changes in LPL protein, validating ANGPTL4 as the post-translational LPL regulator during fasting in humans.\",\n      \"evidence\": \"Prospective human adipose biopsies before/after 26-h fast; cortisol/FFA/insulin treatment of primary human adipocytes\",\n      \"pmids\": [\"32504883\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether visceral adipose behaves identically not assessed\", \"Quantitative relationship between ANGPTL4 protein level and LPL inactivation rate in humans not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Hematopoietic ANGPTL4 deficiency was shown to promote myeloid expansion, foam cell formation, and atherosclerosis via increased CD36 and reduced ABCA1, establishing a macrophage-intrinsic anti-atherogenic role distinct from systemic lipid lowering.\",\n      \"evidence\": \"Bone marrow transplantation in atherosclerosis-prone mice; flow cytometry; CD36/ABCA1 localization assays\",\n      \"pmids\": [\"27460411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mechanism linking ANGPTL4 to ABCA1 surface localization not defined\", \"Whether macrophage ANGPTL4 acts through LPL or a separate pathway not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Hepatocyte-specific ANGPTL4 deletion revealed a liver-autonomous function: inhibition of hepatic lipase (not LPL), controlling remnant lipoprotein catabolism and hepatic fatty acid oxidation.\",\n      \"evidence\": \"Hepatocyte-specific Angptl4 knockout mice; hepatic lipase activity assays; antisense inhibition; AMPK activation assays\",\n      \"pmids\": [\"34255741\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ANGPTL4–hepatic lipase interaction unknown\", \"Whether hepatic ANGPTL4 also inhibits LPL in liver endothelium not excluded\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Large-scale human genetic mimicry analysis confirmed that ANGPTL4's effect on plasma lipids in humans operates exclusively through LPL, not hepatic lipase or endothelial lipase, despite in vitro evidence of EL/HL inhibition.\",\n      \"evidence\": \"Genetic mimicry analysis across >110,000 UK Biobank participants validated in 11 European populations\",\n      \"pmids\": [\"36372100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether tissue-specific HL/EL inhibition has local effects not captured by plasma lipid measurements remains possible\", \"Rare variant effects on non-LPL lipases not powered\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"HDX-MS mapping resolved how ANGPTL4 inhibits LPL: it binds overlapping the APOC2 site and destabilizes lid-anchoring structures, promoting irreversible unfolding of the α/β-hydrolase domain — a fundamentally different mechanism from competitive inhibition.\",\n      \"evidence\": \"Hydrogen-deuterium exchange mass spectrometry; thermal stability assays comparing ANGPTL4 and APOC2 effects on LPL\",\n      \"pmids\": [\"37094117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full atomic-resolution structure of the ANGPTL4–LPL complex not yet available\", \"How oligomeric state of ANGPTL4 modulates unfolding kinetics not determined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of FMNL2-dependent actin polymerization at ANGPTL4-containing vesicles (Rab8a+/myosin Vb+) downstream of TGFβ/PKC revealed a regulated secretory trafficking pathway controlling ANGPTL4 release and cancer cell invasion.\",\n      \"evidence\": \"Super-resolution microscopy; FMNL2 knockdown/phosphorylation mutants; PKC inhibition; invasion assays\",\n      \"pmids\": [\"36691769\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this trafficking pathway operates in non-cancer contexts unknown\", \"Generalizability beyond TGFβ-driven secretion not tested\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that podocyte/tubule-secreted ANGPTL4 binds Integrin β1 and modulates DPP4–Integrin β1 association to drive STING-mediated fibrogenic signaling expanded ANGPTL4's roles beyond lipid metabolism to kidney fibrosis.\",\n      \"evidence\": \"Podocyte- and tubule-specific Angptl4 mutant mice; co-IP between ANGPTL4, Integrin β1, DPP4; STING pathway assays; kidney-targeted antisense inhibition\",\n      \"pmids\": [\"39630889\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of ANGPTL4–Integrin β1 interaction not determined\", \"Whether this pathway operates in non-diabetic kidney disease unknown\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the receptor mediating ANGPTL4's cAMP-dependent intracellular lipolytic signaling, the full atomic structure of the ANGPTL4 oligomer–LPL complex, and how ANGPTL4's metabolic and non-metabolic (inflammatory, ferroptotic, fibrogenic) functions are coordinated in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No receptor identified for ANGPTL4-induced cAMP/lipolysis signaling\", \"No high-resolution structure of full-length ANGPTL4 oligomer bound to LPL\", \"Integration of metabolic and non-metabolic functions in tissue-specific contexts not systematically addressed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 16, 18, 20, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 16, 26]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 3, 9, 11, 12, 16, 19, 21, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 9, 13, 25, 30]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [15, 27, 33]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 5, 28, 29, 31]}\n    ],\n    \"complexes\": [\n      \"ANGPTL4/8 complex\"\n    ],\n    \"partners\": [\n      \"LPL\",\n      \"ANGPTL8\",\n      \"APOC2\",\n      \"FMNL2\",\n      \"IQGAP1\",\n      \"ITGB1\",\n      \"DPP4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}